Soltis Investment Advisors LLC Takes Position in Zoetis Inc. (NYSE:ZTS)

Soltis Investment Advisors LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,106 shares of the company’s stock, valued at approximately $343,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. Quilter Plc grew its holdings in shares of Zoetis by 17.9% during the fourth quarter. Quilter Plc now owns 353,674 shares of the company’s stock worth $57,624,000 after buying an additional 53,596 shares in the last quarter. Wingate Wealth Advisors Inc. acquired a new stake in Zoetis during the fourth quarter worth approximately $63,000. Savant Capital LLC grew its stake in Zoetis by 5.3% in the 4th quarter. Savant Capital LLC now owns 6,271 shares of the company’s stock worth $1,022,000 after acquiring an additional 313 shares during the period. Kestra Private Wealth Services LLC raised its holdings in Zoetis by 6.5% in the 4th quarter. Kestra Private Wealth Services LLC now owns 82,692 shares of the company’s stock valued at $13,473,000 after acquiring an additional 5,027 shares during the last quarter. Finally, Stephens Inc. AR lifted its stake in shares of Zoetis by 22.1% during the 4th quarter. Stephens Inc. AR now owns 59,025 shares of the company’s stock worth $9,617,000 after purchasing an additional 10,681 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the subject of a number of recent analyst reports. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley lowered their price target on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Piper Sandler dropped their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $214.00.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Zoetis Price Performance

Zoetis stock opened at $174.47 on Wednesday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $78.71 billion, a P/E ratio of 32.80, a PEG ratio of 2.77 and a beta of 0.90. The firm has a fifty day moving average of $169.16 and a 200-day moving average of $179.15. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.15%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.